Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Mannin Research

Mannin Research?uq=AFYHfsyn
2012 FOUNDED
M&A STATUS
1-10 EMPLOYEES
Accelerator/Inc LATEST DEAL TYPE
1 INVESTORS
Description

Developer of vascular therapeutics designed to glaucoma and cystic kidney diseases. The company's vascular therapeutics uses Tie2 mechanism of action, enabling medical professional to treat glaucoma and cystic kidney diseases and patients to get relief from these diseases.

Website
Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Accelerator/Incubator Backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Parent Company
Q BioMed
Primary Office
  • 629 Eastern Avenue
  • Suite C300
  • Toronto, Ontario M4M 1E4
  • Canada

+1 (416) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Mannin Research’s full profile, request a free trial.

Mannin Research Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Accelerator/Incubator 02-Feb-2017 Completed Startup
2. Accelerator/Incubator Completed Startup
1. Merger/Acquisition 13-Jan-2016 Completed Startup
To view this company’s complete deal history including valuation and funding, request access »

Mannin Research Former Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
Matter Accelerator/Incubator 000 0000 000000 0

Mannin Research Executive Team (3)

Name Title Board
Seat
Contact
Info
George Nikopoulos Ph.D Chief Executive Officer and President
Susan Quaggin Chief Scientific Officer and Director
Christopher Smith Chairman

Mannin Research Board Members (2)

Name Representing Role Since Contact
Info
Christopher Smith Mannin Research Chairman 000 0000
Geoffrey Smith Mannin Research Board Member 000 0000